Value of Urinary Topoisomerase-IIA Cell-free DNA for Diagnosis of Bladder Cancer

Overview

Journal Investig Clin Urol

Specialty Urology

Date 2016 Mar 17

PMID 26981592

Citations 17

Authors

Ye-Hwan Kim

Chunri Yan

Il-Seok Lee

Xuan-Mei Piao

Young Joon Byun

Pildu Jeong

Won Tae Kim

Seok-Joong Yun

Wun-Jae Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Topoisomerase-II alpha (TopoIIA ), a DNA gyrase isoform that plays an important role in the cell cycle, is present in normal tissues and various human cancers, and can show altered expression in both. The aim of the current study was to examine the value of urinary TopoIIA cell-free DNA as a noninvasive diagnosis of bladder cancer (BC).

Materials And Methods: Two patient cohorts were examined. Cohort 1 (73 BC patients and seven controls) provided bladder tissue samples, whereas cohort 2 (83 BC patients, 54 nonmalignant hematuric patients, and 61 normal controls) provided urine samples. Real-time quantitative polymerase chain reaction was used to measure expression of TopoIIA mRNA in tissues and TopoIIA cell-free DNA in urine samples.

Results: The results showed that expression of TopoIIA mRNA in BC tissues was significantly higher than that in noncancer control tissues (p<0.001). The expression of urinary TopoIIA cell-free DNA in BC patients was also significantly higher than that in noncancer patient controls and hematuria patients (p < 0.001 and p < 0.001, respectively). High expression of urinary TopoIIA cell-free DNA was also detected in muscle invasive bladder cancer (MIBC) when compared with nonmuscle invasive bladder cancer (NMIBC) (p=0.002). Receiver operating characteristics (ROC) curve analysis was performed to examine the sensitivity/specificity of urinary TopoIIA cell-free DNA for diagnosing BC, NMIBC, and MIBC. The areas under the ROC curve for BC, NMIBC, and MIBC were 0.741, 0.701, and 0.838, respectively.

Conclusions: In summary, the results of this study provide evidence that cell-free TopoIIA DNA may be a potential biomarker for BC.

Citing Articles

Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.

Huang F, Di X, Bai M Front Bioeng Biotechnol. 2024; 12:1458362.

PMID: 39295845 PMC: 11408225. DOI: 10.3389/fbioe.2024.1458362.

Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.

Parrao D, Lizana N, Saavedra C, Larranaga M, Lindsay C, San Francisco I Curr Oncol. 2024; 31(4):2201-2220.

PMID: 38668066 PMC: 11048875. DOI: 10.3390/curroncol31040163.

Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.

Rose K, Huelster H, Meeks J, Faltas B, Sonpavde G, Lerner S Nat Rev Urol. 2023; 20(7):406-419.

PMID: 36977797 DOI: 10.1038/s41585-023-00725-2.

Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review.

Koguchi D, Matsumoto K, Shiba I, Harano T, Okuda S, Mori K Int J Mol Sci. 2022; 23(16).

PMID: 36012417 PMC: 9409245. DOI: 10.3390/ijms23169148.

Review of non-invasive urinary biomarkers in bladder cancer.

Lee H, Kim S Transl Cancer Res. 2022; 9(10):6554-6564.

PMID: 35117265 PMC: 8798424. DOI: 10.21037/tcr-20-1990.

References

Costa M, Hansen C, Holden J, Guinee Jr D . Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol. 2000; 19(3):248-57. DOI: 10.1097/00004347-200007000-00009. View

Epstein J, Amin M, Reuter V, Mostofi F . The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22(12):1435-48. DOI: 10.1097/00000478-199812000-00001. View

Strausfeld U, Richter A . Simultaneous purification of DNA topoisomerase I and II from eukaryotic cells. Prep Biochem. 1989; 19(1):37-48. DOI: 10.1080/10826068908544895. View

Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C . Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol. 2001; 166(2):470-5. View

Stenzl A, Cowan N, De Santis M, Kuczyk M, Merseburger A, Ribal M . Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59(6):1009-18. DOI: 10.1016/j.eururo.2011.03.023. View

Nakopoulou L, Zervas A, Lazaris A, Constantinides C, Stravodimos C, Davaris P . Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. J Clin Pathol. 2001; 54(4):309-13. PMC: 1731402. DOI: 10.1136/jcp.54.4.309. View

Simon M, Lokeshwar V, Soloway M . Current bladder cancer tests: unnecessary or beneficial?. Crit Rev Oncol Hematol. 2003; 47(2):91-107. DOI: 10.1016/s1040-8428(03)00074-x. View

Jung K, Won Y, Oh C, Kong H, Cho H, Lee D . Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat. 2015; 47(2):142-8. PMC: 4398104. DOI: 10.4143/crt.2015.066. View

Lynch B, Guinee Jr D, Holden J . Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. 1997; 28(10):1180-8. DOI: 10.1016/s0046-8177(97)90256-2. View

10.

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

11.

van der Poel H, Debruyne F . Can biological markers replace cystoscopy? An update. Curr Opin Urol. 2001; 11(5):503-9. DOI: 10.1097/00042307-200109000-00009. View

12.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59(6):997-1008. DOI: 10.1016/j.eururo.2011.03.017. View

13.

Messing E, YOUNG T, Hunt V, Wehbie J, Rust P . Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer. 1989; 64(11):2361-7. DOI: 10.1002/1097-0142(19891201)64:11<2361::aid-cncr2820641128>3.0.co;2-4. View

14.

Marshall V . Current clinical problems regarding bladder tumors. Cancer. 1956; 9(3):543-50. DOI: 10.1002/1097-0142(195605/06)9:3<543::aid-cncr2820090318>3.0.co;2-0. View

15.

Messing E, YOUNG T, Hunt V, Roecker E, Vaillancourt A, Hisgen W . Home screening for hematuria: results of a multiclinic study. J Urol. 1992; 148(2 Pt 1):289-92. DOI: 10.1016/s0022-5347(17)36575-8. View

16.

Schned A, Andrew A, Marsit C, Scot Zens M, Kelsey K, Karagas M . Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO classification systems. J Urol. 2007; 178(4 Pt 1):1196-200. DOI: 10.1016/j.juro.2007.05.126. View

17.

Messing E, Vaillancourt A . Hematuria screening for bladder cancer. J Occup Med. 1990; 32(9):838-45. DOI: 10.1097/00043764-199009000-00016. View

18.

Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E . Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Ann Surg Oncol. 2014; 22(7):2439-45. DOI: 10.1245/s10434-014-4194-4. View

19.

Kim E, Lee Y, Kim Y, Kim M, Ha Y, Jeong P . Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology. 2009; 75(6):1516.e9-13. DOI: 10.1016/j.urology.2009.08.055. View

20.

Dingemans A, Witlox M, Stallaert R, van der Valk P, Postmus P, Giaccone G . Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res. 1999; 5(8):2048-58. View